Research use only · Multi-region fulfillment · Support-assisted ordering
VestaResearch Supply
Tesamorelin 2mg | 20-Vial Kit | Enhanced GHRH Analog | Adipose & GH Research
ChinaPerformance & Hormone Optimization

Tesamorelin 2mg | 20-Vial Kit | Enhanced GHRH Analog | Adipose & GH Research

$330

In stock

For in vitro laboratory research only. Not for human or veterinary consumption.

China Warehouse Tesamorelin 2mg | 20-Vial Kit — Full-length GHRH(1-44) analogue — FDA-approved mechanism for visceral fat reduction via pulsatile GH stimulation without systemic GH excess. ≥99% HPLC purity, MS confirmed, Janoshik COA. Research use only. International shipping: 7–14 days

SKU
VES-TSM2-TESAMORELIN-2MG-20VIAL
Format
0.42 lbs
Use
Laboratory research only
Ask on Telegram

What is Tesamorelin??

Tesamorelin (CAS 218949-48-9) is a synthetic analogue of endogenous growth hormone-releasing hormone (GHRH) comprising the full 44-amino acid GHRH sequence conjugated to a trans-3-hexenoic acid moiety at the N-terminus — conferring improved stability against DPP-IV degradation and enhanced GHRHr binding. Molecular formula C₂₂₁H₃₆₆N₆₈O₇₀S, MW ~5135 Da. FDA-approved as Egrifta for HIV-associated lipodystrophy, Tesamorelin stimulates pulsatile GH release, which subsequently elevates IGF-1 and drives selective visceral fat reduction — making it the premier GHRH analog for adipose-GH axis research.

Research Applications

Visceral Adipose Research

VAT reduction via GH/IGF-1 axis, lipolysis, FFA mobilisation — lipodystrophy and metabolic syndrome models

GHRHr Signalling

GHRH receptor binding kinetics, Gs/cAMP/PKA cascade, somatotroph cell activation

Pulsatile GH Release

Authentic GHRH-driven GH pulse physiology, IGF-1 axis induction — vs. recombinant HGH

DPP-IV Stability Studies

Trans-3-hexenoic acid N-terminal modification — protease resistance vs. native GHRH and CJC-1295

Metabolic Research

Lipid metabolism, visceral fat, insulin sensitivity, body composition in GH-deficiency models

Quick Specs

Form Lyophilized powder
Purity ≥99% by HPLC — every batch
CAS Number 218949-48-9
Also Known As Egrifta active peptide, TH9507, TransCon GHRH analog
Molecular Formula C₂₂₁H₃₆₆N₆₈O₇₀S
Molecular Weight ~5135 Da
Peptide Type Synthetic GHRH analog — N-terminal trans-3-hexenoic acid modification
Identity MS molecular weight confirmed — every batch
COA Janoshik-independent, publicly verifiable
Manufacture In-house Fmoc SPPS — Qingdao, China
Storage -20°C sealed | 2–8°C reconstituted (2–4 weeks)
Shelf Life 24 months unopened

Certificate of Analysis (COA)

Frequently Asked Questions

How do I reconstitute this peptide?
Add 1–2mL bacteriostatic water to the lyophilized vial by directing water down the inner wall of the vial. Swirl gently until the powder fully dissolves — do not shake or vortex. The solution should be clear and colourless. Use immediately or refrigerate at 2–8°C.
How should this peptide be stored?
Store lyophilized peptide vials at −20°C for long-term storage. Once reconstituted, store at 2–8°C (refrigerator) and use within 21–28 days. Avoid repeated freeze-thaw cycles, direct light, and heat exposure.
What purity is this Vesta compound and how is it verified?
All Vesta compounds are tested to ≥99% purity by HPLC peak area analysis on every production batch. Molecular identity is confirmed by mass spectrometry. A Certificate of Analysis (COA) is published on the product page and independently verifiable at verify.janoshik.com using the batch reference number.
Peptide Research Tools: Use Vesta’s free peptide calculators — reconstitution, BAC water, dosing, half-life, and mixing charts.
International shipping: 7–14 days
Research use only

This material is supplied strictly for in vitro laboratory research. It is not intended for human or veterinary consumption, diagnosis, treatment, or household use.